The offering provides significant cash runway for Erasca's pipeline development but dilutes existing holders by ~10%. Monitor for upcoming clinical data catalysts that could justify the dilution; the upsized offering suggests strong institutional demand, which may support the stock near the $17.50 offering price in the near term.
Price Chart
Executive Summary
Erasca priced an upsized public offering of 31,428,572 shares at $17.50 per share, raising approximately $516 million in net proceeds ($593.5 million if the underwriters' option is exercised in full). The offering provides substantial cash to fund its RAS/MAPK pipeline and general corporate purposes, but dilutes existing shareholders by roughly 10%. The upsized size signals strong institutional demand, partially offsetting dilution concerns.
Key Facts
- Erasca priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share.
- Net proceeds expected to be approximately $516.0 million, or $593.5 million if the underwriters' 30-day option to purchase an additional 4,714,285 shares is exercised in full.
- Underwriters purchase price is $16.45 per share; offering expected to close July 15, 2026.
- Proceeds will be used to fund research and development of product candidates and other development programs, working capital, and general corporate purposes.
- The offering was upsized from the initially proposed $500 million to $550 million in gross proceeds.
Financial Impact
Dilution of approximately 9-11% based on current market cap of $5.6B; cash infusion of ~$516M net ($593.5M with option).
Risk Factors
- Dilution of approximately 9-11% from the new shares.
- Potential overhang from the underwriters' option to purchase additional shares.
- Clinical-stage biotech risk: no approved products; pipeline execution is key.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-303357 |
| Document: d371010d8k.htm | 0001193125-26-303357 |
| Document: d371010dex51.htm | 0001193125-26-303357 |
| Document: d371010dex992.htm | 0001193125-26-303357 |
| Document: d371010dex991.htm | 0001193125-26-303357 |
| Document: 0001193125-26-303357-index-headers.html | 0001193125-26-303357 |
| Document: 0001193125-26-303357-index.html | 0001193125-26-303357 |
| Document: 0001193125-26-303357.txt | 0001193125-26-303357 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access